AU2001294776A1 - Lactone integrin antagonists - Google Patents

Lactone integrin antagonists

Info

Publication number
AU2001294776A1
AU2001294776A1 AU2001294776A AU9477601A AU2001294776A1 AU 2001294776 A1 AU2001294776 A1 AU 2001294776A1 AU 2001294776 A AU2001294776 A AU 2001294776A AU 9477601 A AU9477601 A AU 9477601A AU 2001294776 A1 AU2001294776 A1 AU 2001294776A1
Authority
AU
Australia
Prior art keywords
lactone
integrin antagonists
integrin
antagonists
lactone integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294776A
Inventor
Balekudru Devadas
Jiang Lan
Thomas D Penning
Thomas Rogers
Peter Ruminiski
Jennifer Vancamp
Chester Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001294776A1 publication Critical patent/AU2001294776A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001294776A 2000-09-27 2001-09-27 Lactone integrin antagonists Abandoned AU2001294776A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23561700P 2000-09-27 2000-09-27
US60235617 2000-09-27
US60241633 2000-10-10
US24163300P 2000-10-19 2000-10-19
PCT/US2001/030194 WO2002026227A1 (en) 2000-09-27 2001-09-27 Lactone integrin antagonists

Publications (1)

Publication Number Publication Date
AU2001294776A1 true AU2001294776A1 (en) 2002-04-08

Family

ID=26929086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294776A Abandoned AU2001294776A1 (en) 2000-09-27 2001-09-27 Lactone integrin antagonists

Country Status (6)

Country Link
US (2) US6720327B2 (en)
EP (1) EP1320363A4 (en)
JP (1) JP2004513088A (en)
AU (1) AU2001294776A1 (en)
CA (1) CA2423434A1 (en)
WO (1) WO2002026227A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720327B2 (en) * 2000-09-27 2004-04-13 Pharmacia Corporation Lactone integrin antagonists
US6872708B2 (en) * 2001-09-10 2005-03-29 Mitsukazu Matsumoto Local injection prescription
US20040019206A1 (en) * 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
WO2003080017A1 (en) * 2002-03-19 2003-10-02 The Procter & Gamble Company Liquid personal cleansing compositions containing acyl sarcosinates
DK1615626T3 (en) * 2003-04-24 2010-02-08 Jagotec Ag Colored core tablet
JP5637855B2 (en) * 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Methods and compositions for the treatment of proteinuria

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317957A (en) * 1980-03-10 1982-03-02 Marvin Sendrow System for authenticating users and devices in on-line transaction networks
JP3141144B2 (en) 1992-07-22 2001-03-05 奥野製薬工業株式会社 Silver electrolytic stripping agent
NO943210L (en) * 1993-09-03 1995-03-06 Takeda Chemical Industries Ltd Lactol derivatives, their preparation and use
SE503021C2 (en) * 1994-06-13 1996-03-11 Ericsson Telefon Ab L M Operating support networks for a telecommunications network comprising network elements, telecommunications networks comprising network elements, network elements and ways of structuring software in a network element
US5602155A (en) 1995-01-17 1997-02-11 G. D. Searle & Co. Platelet aggregation inhibitors
US6013651A (en) 1995-08-30 2000-01-11 G. D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof
US6028223A (en) * 1995-08-30 2000-02-22 G. D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
US6720327B2 (en) * 2000-09-27 2004-04-13 Pharmacia Corporation Lactone integrin antagonists

Also Published As

Publication number Publication date
US20020045645A1 (en) 2002-04-18
WO2002026227A1 (en) 2002-04-04
EP1320363A1 (en) 2003-06-25
US6720327B2 (en) 2004-04-13
US6906051B2 (en) 2005-06-14
EP1320363A4 (en) 2004-01-28
CA2423434A1 (en) 2002-04-04
US20040116472A1 (en) 2004-06-17
JP2004513088A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU3213799A (en) Integrin antagonists
AU7315800A (en) Mch antagonists
AU8271101A (en) Titanium-containing materials
AU2001255798A1 (en) Glucagon antagonists
AU2001210928A1 (en) Polypropylene card construction
GB0020432D0 (en) Construction materials
AU2002235224A1 (en) Muscarinic antagonists
AU2001285417A1 (en) Object catcher
AU2002212436A1 (en) Quinazoline derivatives
AU2001234741A1 (en) Integrin antagonists
AU2001279143A1 (en) Metlblown web
AU2001292137A1 (en) Quinazoline derivatives
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU2001239773A1 (en) Baroplastic materials
AU2002228642A1 (en) Footing form
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU6990000A (en) Novel integrin receptor antagonists
AU2001254731A1 (en) Substituted phenyluracils
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2001293131A1 (en) Hydroxy acid integrin antagonists
AU2001294776A1 (en) Lactone integrin antagonists